As presented in Fig. 2A, exposure to the Plk1 inhibitor caused a significant G2/M phase block in all NSCLC cell lines (P < 0.047), accompanied by a significant decrease in number of G1 and S phase cells (both P < 0.001). The gene discussed is PLK1; the disease is non-small cell lung carcinoma.